|
WO2021066144A1
|
|
Pharmaceutical drug containing heterocyclidene acetamide derivative
|
|
WO2021002473A1
|
|
Nrf2-activating compound
|
|
WO2020262497A1
|
|
Novel use of nicotinamide mononucleotide (nmn) and nicotinamide riboside (nr)
|
|
JP2020203884A
|
|
Quality management of preparation containing azithromycin
|
|
JP2020203882A
|
|
Azithromycin-containing ophthalmic agent
|
|
WO2020230869A1
|
|
Composition for preventing or treating neurotrophic keratitis which contains pacap peptide or stabilized pacap peptide
|
|
WO2020230867A1
|
|
Stabilized pacap peptide
|
|
WO2020218488A1
|
|
Eye disease marker
|
|
WO2021065050A1
|
|
Aqueous liquid formulation
|
|
WO2020203822A1
|
|
Combined drug for treating or preventing retinal disease associated with angiogenesis
|
|
WO2020196852A1
|
|
Aqueous formulation
|
|
JP2020075918A
|
|
Ophthalmic composition for promoting corneal epithelium wound cure
|
|
WO2020090705A1
|
|
Retinal ganglion cell death inhibitor
|
|
WO2020071297A1
|
|
Aqueous liquid formulation
|
|
WO2019235456A1
|
|
Aqueous liquid agent
|
|
KR20210015779A
|
|
Ophthalmic liquid formulation with reduced dibutylhydroxytoluene content
|
|
JP2019199470A
|
|
Ophthalmic composition
|
|
JP2019182849A
|
|
Aqueous liquid preparation
|
|
WO2019189720A1
|
|
Aqueous liquid formulation
|
|
WO2019112030A1
|
|
Aqueous liquid agent including water-soluble polymer
|
